Lifecore Biomedical Inc
NASDAQ:LFCR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.815
8.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lifecore Biomedical Inc
Long-Term Debt
Lifecore Biomedical Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Long-Term Debt
$127.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
||
Hershey Co
NYSE:HSY
|
Long-Term Debt
$3.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
||
General Mills Inc
NYSE:GIS
|
Long-Term Debt
$11.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
||
Kellogg Co
NYSE:K
|
Long-Term Debt
$5.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
||
Kraft Heinz Co
NASDAQ:KHC
|
Long-Term Debt
$19.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
||
Mondelez International Inc
NASDAQ:MDLZ
|
Long-Term Debt
$16.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Long-Term Debt?
Long-Term Debt
127.2m
USD
Based on the financial report for Aug 25, 2024, Lifecore Biomedical Inc's Long-Term Debt amounts to 127.2m USD.
What is Lifecore Biomedical Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
14%
Over the last year, the Long-Term Debt growth was 19%. The average annual Long-Term Debt growth rates for Lifecore Biomedical Inc have been 1% over the past three years , 8% over the past five years , and 14% over the past ten years .